CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

VOLUNTARY ANNOUNCEMENT
INITIATION OF PHASE III CLINICAL TRIAL AND COMPLETION OF FIRST PATIENT ENROLLMENT FOR DTCP INFANT

This announcement is made by CanSino Biologics Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The Company is pleased to announce that, the phase III trial for DTcP vaccine for infants (below 2 years old) ("**DTcP Infant**") developed by the Group, was officially initiated recently and the first trial patient case has been formally enrolled.

BASIC INFORMATION ABOUT THE PRODUCT

The manufacturing process of the co-purified diphtheria, tetanus and acellular pertussis vaccine (the "**DTaP**") currently available in China uses a process of co-purification of pertussis antigens. As a diphtheria, tetanus and acellular pertussis (components) vaccine, each pertussis antigen of the DTcP Infant can be purified separately and formulated in a defined ratio, thus ensuring batch-to-batch consistency of product quality and making the product more stable.

As of the date of this announcement, no component vaccine for diphtheria, tetanus and acellular pertussis developed by domestic vaccine manufacturers has been approved for marketing in China. Our DTcP Infant is positioned as an alternative to imports. Meanwhile, the development of DTcP Infant also lays a solid foundation for the further development of our Tdcp Adolescent and Adult and CS-2201 DTcP Components Combined Vaccine. The product portfolio of diphtheria, tetanus and acellular pertussis (components) vaccine will further enrich the Company's product strategy and enhance the Company's core competitiveness.

CLINICAL STUDIES

Results of Phase I clinical trial of DTcP Infant showed its great safety profile. No Grade 3 adverse reactions or vaccine-associated serious adverse events (SAE) occurred.

Based on the results obtained in Phase I clinical trial, Phase III clinical trial will evaluate the safety and immunogenicity of DTcP Infant in infants and children aged 2 months and 3 months, and conduct a randomized, blinded, positive control clinical trial.

We cannot guarantee that we will ultimately develop or commercialize DTcP Infant successfully. Considering several unpredictable factors in the process of clinical trials and the results and timing of clinical trials, evaluations and approvals are subject to uncertainty. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, August 13, 2023

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU, Dr. Dongxu QIU and Ms. Jing WANG as executive directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive directors.